Cancer patients face higher risk for shingles, new vaccines hold promise for prevention

People newly diagnosed with cancer, particularly blood cancers, and those treated with chemotherapy have a greater risk of developing shingles, according to a new study in the Journal of Infectious Diseases. The findings may help guide efforts to prevent the often painful skin condition in cancer patients through the use of new vaccines. The large prospective study expands on previous research by examining the risk of shingles before and after a new cancer diagnosis and across a range of cancer types among approximately 240,000 adults in Australia from 2006 to 2015.

Shingles, or herpes zoster, is caused by the varicella zoster virus, the same virus that causes chickenpox. Shingles develops when the virus, which remains dormant in the body, reactivates later in life. Nearly one in three people in the U.S. will develop shingles in their lifetime, and there are an estimated 1 million cases in the country each year, according to the U.S. Centers for Disease Control and Prevention.

In the study, researchers found that, overall, a cancer diagnosis of any kind was associated with about a 40 percent increase in risk for developing shingles compared to the risk in someone without cancer. Patients with a blood-related, or hematological, cancer diagnosis had a more than three-fold higher risk of developing shingles than people without cancer. Individuals with a diagnosis of cancer related to a solid tumor, such as cancer located in the lung, breast, prostate or other organ, had a 30 percent higher shingles risk compared to someone with no cancer.

The new analysis in the Journal of Infectious Diseases also found that the higher risk for shingles among patients with blood cancers was present in the two years before their cancer diagnosis, according to the study’s first author, Jiahui Qian, MPH, of the University of New South Wales in Sydney, Australia. However, for patients with solid tumors, the higher risk of developing shingles appeared to be largely associated with receiving chemotherapy after their diagnosis, rather than with the cancer itself. In examining the higher risk of shingles in cancer patients, few previous studies have separated the risk for shingles associated with a patient’s cancer from the risk associated with chemotherapy.

“These findings have important implications in view of recent advances in development of zoster vaccines,” wrote Kosuke Kawai, ScD, of Boston Children’s Hospital and Harvard Medical School and Barbara P. Yawn, MD, MsC, of the University of Minnesota, in a related editorial commentary that appears with the new study in the Journal of Infectious Diseases. The commentary authors were not involved in the research.

A new shingles vaccine approved for use in the U.S. in 2017 does not use a live form of the virus and is likely to be safe in people with compromised immune systems, such as those on chemotherapy. The vaccine is not yet recommended for these individuals in the U.S., as public health officials await more data on the vaccine’s use in such patients. Another new shingles vaccine that uses an inactivated form of the virus is also in development. These advances suggest that vaccination holds great promise as a strategy to prevent shingles and its complications in cancer patients, the commentary and study authors both noted.

• Shingles, or herpes zoster, is an often painful skin condition caused by the same virus that causes chickenpox, when the virus reactivates later in life.

• People newly diagnosed with cancer, particularly blood-related cancers, and those treated with chemotherapy have a greater risk of developing shingles compared to patients without cancer, according to a new study.

• The findings may help guide efforts to prevent shingles and its related complications in cancer patients through the use of new vaccines that do not use a live form of the shingles-causing virus.

###

Editor’s note: The study was funded by the Australian National Health and Medical Research Council. The study authors’ and editorial commentary authors’ affiliations, acknowledgments, and disclosures of financial support and potential conflicts of interests, if any, are available in the study and the commentary, which are embargoed until 12:05 a.m. ET on Thursday, Dec. 13. For an embargoed copy of the study and the commentary, please contact Samantha Guckenberger (312-558-1770, [email protected]).

Published continuously since 1904, the Journal of Infectious Diseases is the premier global journal for original research on infectious diseases. The editors welcome major articles and brief reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses. The journal is an official publication of the Infectious Diseases Society of America (IDSA). Based in Arlington, Va., IDSA is a professional society representing more than 11,000 physicians and scientists who specialize in infectious diseases. For more information, visit http://www.idsociety.org. Follow IDSA on Facebook and Twitter.